dismiss

This Thursday, Jan 25th is our next Clean Sweep Live Auction: Click to view the full catalogue and pre-bid now

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Cardiology Homepage

One-of-a-kind TTE cardiac imaging probe invented to better train cardiologists A safe and realistic simulator

Dr. Prem Soman American Society of Nuclear Cardiology names 2018 president

Lower costs and rapid care for cardiology patients tied to eConsults May save payors more than $400 per patient

Donald Trump had a CT scan, here's what we learned President deemed healthy, despite presence of heart disease

Canadian resident pleads guilty in U.S. health care scam Sold device under false pretense of treating more than 200 diseases

FDA gives nod to MR-conditional labeling for Abbott ICD and CRT-D Labeling will reduce anxiety for patients who need scanning

Corindus and Mayo Clinic partner to study telestenting Can the CorPath GRX enable more patients to undergo PCI?

Alex Gorsky The American Heart Association names Johnson & Johnson Chairman & CEO as chairman of its CEO roundtable

Personalized medicine: The future of cardiology New technologies are improving cardiac care

Physicians halt life-threatening arrhythmias with stereotactic radiation First entirely noninvasive process proposed for treating ventricular tachycardia

MyoVista high sensitivity
electrocardiograph Testing Device

New advanced ECG tool for cardiac disease now available in Europe

by John R. Fischer , Staff Reporter
European cardiologists may soon be able to detect the presence of heart disease more effectively in patients, thanks to a new advanced ECG tool.

HeartSciences’ MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device is now available for sale and distribution in markets across the European Union, following CE approval.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory



“Our device performs all of the functions that normal resting ECG does that you would expect in a higher performance 12-lead, resting ECG that hospitals would use, for instance,” Mark Hilz, president and CEO of HeartSciences, said. “Our device performs all those functions, plus it provides additional informatics that will provide additional information related to cardiac dysfunction.”

MyoVista hsECG uses continuous wavelet transform, an advanced form of signal processing, to transform ECG signals into energy distribution during the cardiac cycle. Traditional ECG only examines analog waveforms of signals.

The device then analyzes the signals to measure the energy of the heart during each heartbeat, especially during its resting stage, with HeartSciences asserting that the use of continuous wavelet transform increases the sensitivity of detection in the device for the presence of cardiac disease.

“Once we’ve transformed the wave form, we look at the T-form, the resting stage, which is when sub-clinical heart disease typically manifests itself,” Hilz said. “So, if you have structural disease such as valve disease or hypotrophy or cardiomyopathy, or you have coronary arterial disease, it’s typically going to be seen in the resting phase or the diastolic phase, which is when the T-wave occurs.”

A trial conducted for the presence of left ventricular diastolic dysfunction in 200 patients found that the devices showed 88% sensitivity and 87% specificity in detecting cardiac dysfunction in the diastolic phase of the cardiac cycle.

It uses the same 12-lead, at-rest testing protocol as traditional ECG, making it easier for physicians and clinical staff to quickly assimilate it for use. But the device can also act as one single test, is less costly than traditional ECG tools, may be used on asymptomatic patients, and could be used to detect cardiac disease in patients at an earlier stage.

“ECG technology has been around for a hundred plus years. For a hundred plus years, they’ve been looking at that normal cardiac monitor wave form, and we are the first ones to use signal processing to transform the waveform … we’ve transformed the waveform and found very useful data on whether heart disease is present, whether there is true dysfunction related to structural or coronary arterial disease.”

HeartSciences is currently working to obtain approval for MyoVista hsECG in Australia, Canada, Latin America, the Middle East and Asia-Pacific. It is seeking to submit the device for FDA approval in 2018.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED